id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-005446-jr3yj4o2	Forrest, D L	Low molecular weight heparin for the prevention of hepatic veno-occlusive disease (VOD) after hematopoietic stem cell transplantation: a prospective phase II study	2003-06-10		.txt	text/plain	4931	278	46	title: Low molecular weight heparin for the prevention of hepatic veno-occlusive disease (VOD) after hematopoietic stem cell transplantation: a prospective phase II study We evaluated 40 patients undergoing high-dose chemo/ radiotherapy (HDCT) and hematopoietic stem cell transplantation (HSCT) (allogeneic (22) , autologous (18) ) to determine the safety and feasibility of administering low molecular weight heparin (LMWH) as hepatic veno-occlusive disease (VOD) prophylaxis. We evaluated 40 patients undergoing high-dose chemo/ radiotherapy (HDCT) and hematopoietic stem cell transplantation (HSCT) (allogeneic (22) , autologous (18) ) to determine the safety and feasibility of administering low molecular weight heparin (LMWH) as hepatic veno-occlusive disease (VOD) prophylaxis. Daily patient evaluation while receiving dalteparin included patient weight, oxygen saturation, liver size, presence of right upper quadrant (RUQ) abdominal pain, ascites or pleural effusions, complete blood count (CBC), serum creatinine, assessment of bleeding and GVHD; adverse events, grading of RRT and the number of red cell and platelet transfusions were recorded; liver function tests (bilirubin, AST, ALT, alkaline phosphatase), INR, PTT and fibrinogen were measured twice weekly.	./cache/cord-005446-jr3yj4o2.txt	./txt/cord-005446-jr3yj4o2.txt